Financial Comparison: Agile Therapeutics (AGRX) & Keryx Biopharmaceuticals (KERX)
Agile Therapeutics (NASDAQ: AGRX) and Keryx Biopharmaceuticals (NASDAQ:KERX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.
Volatility and Risk
Agile Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Keryx Biopharmaceuticals has a beta of 5.13, indicating that its stock price is 413% more volatile than the S&P 500.
Institutional and Insider Ownership
67.6% of Agile Therapeutics shares are owned by institutional investors. Comparatively, 65.2% of Keryx Biopharmaceuticals shares are owned by institutional investors. 3.5% of Agile Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Keryx Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of current recommendations for Agile Therapeutics and Keryx Biopharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agile Therapeutics presently has a consensus price target of $10.20, indicating a potential upside of 104.41%. Keryx Biopharmaceuticals has a consensus price target of $7.50, indicating a potential upside of 15.38%. Given Agile Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Agile Therapeutics is more favorable than Keryx Biopharmaceuticals.
This table compares Agile Therapeutics and Keryx Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Agile Therapeutics and Keryx Biopharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Agile Therapeutics||N/A||N/A||-$29.00 million||($0.97)||-5.14|
|Keryx Biopharmaceuticals||$42.83 million||18.02||-$121.75 million||($1.69)||-3.85|
Agile Therapeutics has higher revenue, but lower earnings than Keryx Biopharmaceuticals. Agile Therapeutics is trading at a lower price-to-earnings ratio than Keryx Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Agile Therapeutics beats Keryx Biopharmaceuticals on 10 of the 12 factors compared between the two stocks.
About Agile Therapeutics
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.